Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS trial of rivaroxaban to prevent major cardiovascular events in coronary or peripheral artery disease
2012-004180-43Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in coronary arteriosclerosis, arteriosclerosis obliterans and None (4 arms), sponsored by Bayer. Started Jan 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on 2012-004180-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004180-43.